233 related articles for article (PubMed ID: 15607729)
1. No inhibition of IL-27 signaling by soluble gp130.
Scheller J; Schuster B; Hölscher C; Yoshimoto T; Rose-John S
Biochem Biophys Res Commun; 2005 Jan; 326(4):724-8. PubMed ID: 15607729
[TBL] [Abstract][Full Text] [Related]
2. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
3. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
4. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.
Liu XH; Kirschenbaum A; Lu M; Yao S; Klausner A; Preston C; Holland JF; Levine AC
Biochem Biophys Res Commun; 2002 Jan; 290(1):249-55. PubMed ID: 11779161
[TBL] [Abstract][Full Text] [Related]
6. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury.
Klein C; Wüstefeld T; Assmus U; Roskams T; Rose-John S; Müller M; Manns MP; Ernst M; Trautwein C
J Clin Invest; 2005 Apr; 115(4):860-9. PubMed ID: 15761498
[TBL] [Abstract][Full Text] [Related]
7. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy.
Selander KS; Li L; Watson L; Merrell M; Dahmen H; Heinrich PC; Müller-Newen G; Harris KW
Cancer Res; 2004 Oct; 64(19):6924-33. PubMed ID: 15466183
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
10. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
13. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.
Hirano T; Ishihara K; Hibi M
Oncogene; 2000 May; 19(21):2548-56. PubMed ID: 10851053
[TBL] [Abstract][Full Text] [Related]
14. STAT3 is dispensable for maintenance of self-renewal in nonhuman primate embryonic stem cells.
Sumi T; Fujimoto Y; Nakatsuji N; Suemori H
Stem Cells; 2004; 22(5):861-72. PubMed ID: 15342949
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
16. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms mediating the inhibitory effect of all-trans retinoic acid on primitive hematopoietic stem cells in human long-term bone marrow culture.
Sammons J; Ahmed N; Khokher MA; Hassan HT
Stem Cells; 2000; 18(3):214-9. PubMed ID: 10840075
[TBL] [Abstract][Full Text] [Related]
18. [Abnormal gp130 signaling and autoimmune disease].
Ishihara K; Atsumi T
Tanpakushitsu Kakusan Koso; 2002 Dec; 47(16 Suppl):2336-42. PubMed ID: 12518458
[No Abstract] [Full Text] [Related]
19. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor.
Skiniotis G; Boulanger MJ; Garcia KC; Walz T
Nat Struct Mol Biol; 2005 Jun; 12(6):545-51. PubMed ID: 15895091
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
